^
Association details:
| Biomarker: | HES1 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Abstract CT044: Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)
Published date:
04/28/2020
Excerpt:
Gene expression related to Notch pathway activation (i.e. high expression of HES1) appeared to be associated with lack of response to atezo + bev (p < 0.039) and shorter PFS (HR = 2.1 [1.3-3.6]).
DOI:
10.1158/1538-7445.AM2020-CT044
Trial ID:
